Nkmax Co Ltd 182400
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- KRW 1,844.00
- Day Range
- KRW 1,815.00–2,085.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 0.00 / KRW 0.00
- Market Cap
- —
- Volume/Avg
- 3.8 Mil / 5.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- 3.51
- Price/Sales
- 15.09
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nkmax Co Ltd engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The firm provides prevention for diseases like Cancer, Aging and contagious diseases, Autoimmune diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 133
- Website
- https://www.nkmax.com/eng
Comparables
Valuation
|
Metric
|
182400
|
215600
|
298380
|
|---|---|---|---|
Price/Earnings (Normalized) | 3.51 | — | 293.95 |
Price/Book Value | 1.54 | 10.25 | 26.86 |
Price/Sales | 15.09 | 125.90 | 18.61 |
Price/Cash Flow | — | — | 264.56 |
Price/Earnings
182400
215600
298380
Financial Strength
|
Metric
|
182400
|
215600
|
298380
|
|---|---|---|---|
Quick Ratio | 0.11 | 4.86 | 1.71 |
Current Ratio | 0.20 | 5.10 | 1.81 |
Interest Coverage | −30.04 | −12.59 | −0.83 |
Quick Ratio
182400
215600
298380
Profitability
|
Metric
|
182400
|
215600
|
298380
|
|---|---|---|---|
Return on Assets (Normalized) | 3.12% | −21.75% | 1.19% |
Return on Equity (Normalized) | 7.44% | −33.19% | 3.85% |
Return on Invested Capital (Normalized) | 4.32% | −25.15% | 2.44% |
Return on Assets
182400
215600
298380
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nzjhwvdqcq | Cjds | $547.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Szyldtdy | Nbtysp | $105.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Frttlktwj | Glnjz | $103.7 Bil | |
MRNA
| Moderna Inc | Ynvmxqgs | Ltmlp | $46.8 Bil | |
ARGX
| argenx SE ADR | Htkmfxmjx | Gwvy | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Hvxzbpw | Pgth | $22.5 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mzgpwfx | Bwklfl | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zqxdlnwb | Xpvfbr | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ljcsvgqwl | Ygvmnmj | $12.8 Bil | |
INCY
| Incyte Corp | Bzyxhrs | Htnbwhy | $12.1 Bil |